Eli Lilly and Novo Nordisk have agreed pricing deals for GLP-1RA brands, a pivotal moment in the obesity treatment market.
Caplyta’s MDD label extension marks the first approval since J&J acquired the drug in a $14.6bn buyout.
The EMA's CHMP has recommended the approval of Gobivaz throughout the European Economic Area.
The partnership is to address early-stage development challenges.
Linzess becomes the first FDA-approved treatment for IBS-C in paediatric patients.
Novo Nordisk has already submitted for approval of oral semaglutide in obesity with the FDA.
